探讨腹腔镜下胰腺中段主胰管邻近区域肿瘤剜除术(laparoscopic enucleation of pancreatic tumors, LapEN)的临床应用效果和安全性。

回顾分析2023年1月至2024年12月期间，电子科技大学附属绵阳市中心医院肝胆胰脾外科8例接受LapEN术治疗胰腺中段良性或低度恶性肿瘤且与主胰管关系密切患者的临床资料。记录手术时间、术中出血量、术后胰瘘及其他并发症发生情况，并评估远期胰腺功能保护效果。

8例患者手术顺利完成，平均手术时间125.0±52.98 min，术中出血量58.7±29.00 ml。所有患者术后均发生胰瘘，其中B级胰瘘3例(37.5%)，经保守治疗或轻微干预后均顺利恢复，无重度胰瘘或严重并发症发生。随访期间(中位随访13.5个月)，无肿瘤复发及新发糖尿病。

在精细的手术技术支持下，LapEN治疗胰腺中段邻近主胰管的良性或低度恶性肿瘤安全有效，尽管胰瘘发生率较高，但临床可控，远期胰腺功能保护良好。

To explore the safety and clinical outcomes of laparoscopic enucleation (LapEN) for middle pancreatic tumors adjacent to the main pancreatic duct.

Clinical data of 8 patients who underwent LapEN for benign or borderline tumors closely adjacent to the main pancreatic duct from Jan. 2023 to Dec. 2024 were retrospectively analyzed. Surgical time, intraoperative blood loss, postoperative pancreatic fistula (POPF), and other complications were recorded, and long-term preservation of pancreatic function was evaluated.

All 8 cases were successfully completed laparoscopically. The mean operative time was 125.0±52.98 min, and intraoperative blood loss was 58.7±29.00 ml. All patients developed POPF postoperatively, including 3 cases (37.5%) of grade B fistula, which were successfully managed conservatively or with minimal intervention. No severe POPF or major complications occurred. During the follow-up period (median follow-up of 13.5 months), no tumor recurrence or new-onset diabetes was observed.

With precise surgical techniques, LapEN is safe and effective for benign or borderline tumors adjacent to the main pancreatic duct in the middle pancreas. Despite a relatively high incidence of POPF, clinical management was feasible, and good long-term pancreatic function was preserved.